Brief: Synact Pharma Reports Preclinical Data
09/07/2026 12:25
BRIEF-Synact Pharma Reports Preclinical Data July 9 (Reuters) - SynAct Pharma AB SYNACT.ST:
REPORTS PRECLINICAL DATA SHOW RESOMELAGON REDUCES OSTEOARTHRITIS INFLAMMATION AND JOINT DAMAGE
PRESENTS PRECLINICAL RESULTS WITH RESOVIR AND UNIVERSIDADE FEDERAL DE MINAS GERAIS
Source text: ID:nMFNX0kc3
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development